Kyowa Hakko Kirin Co., Ltd. (KY4.F)
| Previous close | 16.00 |
| Open | 15.90 |
| Bid | 15.80 x 129600 |
| Ask | 16.40 x 126400 |
| Day's range | 15.90 - 15.90 |
| 52-week range | 14.00 - 20.00 |
| Volume | |
| Avg. volume | 3 |
| Market cap | 8.636B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 24.46 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.36 (2.28%) |
| Ex-dividend date | 27 Jun 2024 |
| 1y target est | N/A |
- Business Wire
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
TOKYO, April 15, 2024--On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, "Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)", a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subt
- PR Newswire
Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
Kyowa Kirin Co., Ltd. (TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, today announced that pre-clinical data of tivozanib (KHK-4951), an investigational product, assessing the ocular pharmacokinetics of a novel tivozanib eye drop for neovascular age-related macular degeneration (nAMD), will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to b
- PR Newswire
Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product in patients with moderate-to-severe atopic dermatitis (msAD), will be presented at the American Academy of Dermatology (AAD) 2024 Annual Meeting to be held in San Diego from March 8-12, 2024.
